Fludarabine
Immunoproliferative Disorders
UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Immunoproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
Ibrutinib Oncternal Therapeutics, Inc | Phase 3 | B |
Jcar017 (Lisocabtagene Maraleucel) Juno Therapeutics, a Subsidiary of Celgene | Phase 2 | B |
Tucidinostat Fudan University | Phase 2 | CCC |
Atlcar.Cd30.Ccr4 Cells UNC Lineberger Comprehensive Cancer Center | Phase 1 | CC |
View all 12 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →